ASSOCIATION OF THE PI3K/AKT/mTOR/NF-κB PATHWAY WITH CELLULAR CANNIBALISM IN GIANT CELL LESION: AN IMMUNOHISTOCHEMICAL STUDY
Giant Cells; Giant Cell Tumors; Granuloma, Giant Cell; PTEN Phosphohydrolase; Regulatory-Associated Protein of mTOR; Immunohistochemistry
The maxillofacial region can be affected by giant cell lesions (GCLs) that exhibit distinct clinical behavior and nature. Among them, central giant cell granulooma (CGCG) is a benign, sometimes osteolytic and destructive lesion composed of osteoclast-like giant cells, some of which are cannibalistic, along with mononuclear cells. The mechanisms associated with the different biological behaviors of these lesions remain incompletely understood. In this context, this dissertation aimed to investigate the clinical, radiographic, genomic, and proteomic profiles of giant cell lesions of the maxillofacial bones, as well as to determine whether the PI3K/mTOR pathway is involved in their pathogenesis. To achieve this, an occurrence study was conducted, encompassing all cases presenting giant cells in their morphology diagnosed at the Oral Pathology Service of the Department of Dentistry at the Universidade Federal do Rio Grande do Norte between 1970 and 2023. It was identified that the peripheral gian cell granuloma (PGCG) was the most prevalent (n = 169), followed by CGCG (n = 104). To identify the molecular alterations present in CGCG, a scoping review was conducted, which, among other findings, highlighted that the PI3K/AKT/mTOR signaling pathway may play a role in the pathogenesis of CGCG. Accordingly, through an immunohistochemical study, we analyzed the influence of the PI3K/AKT/mTOR pathway on the biological behavior of PGCL, CGCG (both aggressive and non-aggressive), and giant cell tumor (GCT) of long bones. Our findings indicated that mTOR and PTEN do not appear to influence the differences in biological behavior observed among these lesions. Additionally, it was identified that p-S6 expression influences the biological behavior of GCLs independently of mTOR.